伊利帕西 T67991

Product Introduction
Bioactivity


英文名: Iliparcil

描述: Iliparcil 是一种具有口服活性的抗血栓化合物。

体内活性: The effect of Iliparcil, a new orally active beta-D-xyloside venous antithrombotic, was studied on the thrombosis following thrombolytic therapy in rats, using a modified Umetsu model. The compound was administered by oral route prior to thrombolytic therapy, which consisted of administering a combination of heparin and urokinase (H/U) at 37.5 and 70,000 IU/kg, respectively. Time to occlusion increased from 3.9 min with saline to 10.5 min following H/U injection. When Iliparcil (30 mg/kg, oral route) was administered 4 h before H/U injection, the time to occlusion was increased by 250% compared with H/U alone (p < 0.001). Similarly, dermatan sulfate (DS), administered intravenously (3 mg/kg) 5 min before thrombus induction, also increased the time to occlusion (300% compared with H/U alone; p < 0.001). It was also shown that times to occlusion following Iliparcil or DS treatments were still increased even when heparin dosage was decreased.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (147.76 mM)


相关库: Bioactive Compounds Library Max | Bioactive Compound Library

伊利帕西 T67991信息由TargetMol中国为您提供，如您想了解更多关于伊利帕西 T67991报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途